| 抗肿瘤血管新药的研究进展 |
| |
| 引用本文： | 陈 娇,徐为人. 抗肿瘤血管新药的研究进展[J]. 现代药物与临床, 2012, 27(1): 1-5 |
| |
| 作者姓名： | 陈 娇 徐为人 |
| |
| 作者单位： | 1. 天津药物研究院天津市新药设计与发现重点实验室,天津300193;天津医科大学,天津300070
2. 天津药物研究院天津市新药设计与发现重点实验室,天津,300193 |
| |
| 基金项目： | 国家自然科学基金项目（81072694, 30873118） |
| |
| 摘 要： | 目前肿瘤血管靶向治疗新药的研究主要集中在两个方向,即肿瘤血管生成抑制剂(tumor angiogenesis inhibitor,TAI)和肿瘤血管靶向制剂(vascular targeting agent,VTA).TAI类旨在抑制肿瘤血管生成的过程,近年来研究较多的为血管内皮生长因子(VEGF)类、基质金属蛋白酶(MMP)类、血管抑素类、内皮抑素类等；而VAT类则是通过破坏肿瘤组织中已存在的血管从而使肿瘤坏死,主要包括小分子类VTA和生物类VTA.对近年来各类抗肿瘤血管治疗新药的种类、作用机制及各自的临床研究进展进行综述.
|
| 关 键 词： | 肿瘤血管生成抑制剂(TAI) 内皮生长因子(VEGF) 基质金属蛋白酶(MMP) 肿瘤血管靶向制剂(VTA) |
| 收稿时间： | 2011-11-12 |
Progress on anti-angiogenesis new drugs |
| |
| CHEN Jiao and XU Wei-ren. Progress on anti-angiogenesis new drugs[J]. Drugs & Clinic, 2012, 27(1): 1-5 |
| |
| Authors: | CHEN Jiao and XU Wei-ren |
| |
| Affiliation: | CHEN Jiao;XU Wei-ren; |
| |
| Abstract: | Nowadays two aspects were involved in research on new drugs of tumor vascular targeting therapy, including tumorangiogenesis inhibitor (TAI) and vascular targeting agent (VTA). TAI aimed to inhibit the process of new angiogenesis and the moststudied TAI agents were VEGF TAI, MMP TAI, angiostatin, endostatin and so on. The VTA induced a tumor necrosis throughdestroying vessels in tumor tissue, mainly including small molecularVTA and biological VTA. This review summarizes the types ofanti-angiogenesis drug, their molecule mechanisms and the clinical research progress. |
| |
| Keywords: | tumor angiogenesis inhibitors (TAI) VEGF MMP vascular targeting agent (VTA) small molecule VTA biologicalVTA |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
| 点击此处可从《现代药物与临床》浏览原始摘要信息 |
|
点击此处可从《现代药物与临床》下载全文 |
|
